The sentence often ends a report written for a different question: "Small cystic lesion in the head of the pancreas, most likely a branch-duct IPMN." A quick online search leads straight to pancreatic cancer, one of the deadliest cancers. The good news first: most pancreatic cysts found by chance stay harmless for life. The harder news: a few are precursors of cancer. The task is to recognise those few without turning everyone else into lifelong patients, or operating for nothing.

How common are pancreatic cysts?

The closer you look and the older the person, the more you find. A meta-analysis of 17 studies with 48,860 people without symptoms found cysts in 8% on average: 24.8% with the particularly sensitive MR cholangiopancreatography (MRCP), 2.7% on CT. In the population-based SHIP study from north-eastern Germany, which counted cysts from 2 mm on MRI, almost half of participants had one: 17.1% of those aged 30–39, 75.7% of those over 80. Most were tiny; none developed pancreatic cancer within five years. Nearly all are found by chance, for instance on a whole-body MRI; see also our article on incidental findings in the liver, kidney and adrenal gland.

8%people without symptoms with a pancreatic cyst (meta-analysis)
75.7%over-80s with a cyst ≥2 mm on MRI (SHIP study)
0.7%with worrisome features or high-risk stigmata (meta-analysis)

Not every cyst is the same

  • Pseudocysts are walled-off fluid after inflammation of the pancreas (pancreatitis). They are not a growth and do not turn malignant.
  • Serous cystadenomas are benign; according to the European guideline they practically never behave malignantly and are removed only if they cause symptoms.
  • Mucinous cystic neoplasms (MCN) produce mucus and usually lie in the body or tail of the gland. They can become malignant; removal is advised from 40 mm, or with symptoms or a wall nodule.
  • Intraductal papillary mucinous neoplasms (IPMN) are the most common incidental finding and grow within the duct system. If only a side branch is involved (branch-duct IPMN), the risk is low; if the main duct is involved (main-duct or mixed type), it is high.
  • Solid pseudopapillary neoplasms (SPN) are rare; the European guideline recommends removing all of them.
  • Cystic neuroendocrine tumours arise from hormone-producing cells, with a malignancy risk of about 20%; those over 20 mm are removed.

How high is the cancer risk?

For the typical small branch-duct IPMN without warning signs, low. In a US population study of 2,114 people aged 50 and over, followed for a median of twelve years, the cancer rate in such IPMNs was 0.16 per 100 person-years, about 1.6 per 1,000 people per year, against 0.11 in people without an IPMN; the difference was not statistically significant. The American Gastroenterological Association (AGA) estimated malignant change across all cysts at about 0.24% per year. Main-duct involvement is different: the European guideline reports malignancy rates of 30 to 90% once the duct is wider than 5 mm.

Worrisome features and high-risk stigmata

Guidelines distinguish two groups of warning signs. "High-risk stigmata" point strongly to cancer or an immediate precursor; "worrisome features" signal increased risk that needs closer work-up.

Worrisome features (Kyoto 2024)

Cyst 30 mm or larger; growth of 2.5 mm or more per year; thickened, enhancing wall; wall nodule under 5 mm; main duct 5–9 mm; abrupt change in duct calibre with shrinkage of the gland beyond; enlarged lymph nodes; raised CA 19-9; acute pancreatitis; new-onset diabetes.

High-risk stigmata (Kyoto 2024)

Jaundice from a cyst in the head of the pancreas; enhancing wall nodule or solid component of 5 mm or more; main duct 10 mm or wider; suspicious or positive cytology.

The European guideline (2018) is more lenient on size and growth: a cyst of 40 mm or more, growth of 5 mm or more per year, CA 19-9 above 37 U/ml, or new diabetes or pancreatitis count as relative indications for surgery.

Without warning signs, cysts are watched, usually with MRI/MRCP: per the European guideline every six months in the first year, then yearly. Kyoto grades by size: cysts under 20 mm at 6 months, then every 18 months if stable; 20–30 mm twice at 6-month intervals, then yearly; 30 mm and over every 6 months. Worrisome features add endoscopic ultrasound (from inside the stomach, with an optional needle sample); high-risk stigmata lead to surgery in anyone fit for it. The German S3 guideline on pancreatic cancer (version 3.1, 2024; S3 is the highest tier of German guidelines) recommends endoscopic ultrasound for cysts over 1 cm or when the diagnosis is unclear and defers IPMN treatment decisions to the European and international guidelines.

When surgery is needed

In the head of the pancreas, this usually means a Whipple operation: the pancreatic head, duodenum, gallbladder and lower bile duct are removed and the digestive tract reconnected. In the tail, a distal pancreatectomy, often including the spleen, is usually enough. The AGA review gives a mortality of about 2% and major complications in about 30%. In Germany, among 60,858 pancreatic operations in 2009–2014, in-hospital mortality was 11.5% at very-low-volume and 6.5% at very-high-volume hospitals. Since 2025, the Federal Joint Committee (G-BA), which sets binding rules for statutory insurance, requires at least 20 complex pancreatic operations in adults per hospital site and year. See also choosing a hospital for surgery.

Hence the dilemma: in surgical series, the AGA notes, only about 15% of removed cysts contained invasive cancer. Operating on harmless cysts exposes people to real risks (complications, sometimes diabetes or digestive problems) for no gain; overlooking high-risk stigmata may waste the chance to remove a cancer before it develops. Both are errors.

When can surveillance stop?

The guidelines differ. The European guideline advises continuing as long as the person is fit for surgery. The AGA (US, 2015) suggests stopping after five years without significant change; the American College of Radiology foresees 9 to 10 years, ending at around 80. Kyoto 2024 offers two options for branch-duct IPMNs under 20 mm that have been stable for five years: stop, or continue, partly because a cancer can arise elsewhere in the gland. An international study of 3,844 patients supports stopping in older people: after five stable years, cancer risk matched the general population for people over 75 with cysts under 30 mm and over 65 with cysts of 15 mm or less. Lifelong follow-up costs money and time, and each appointment can bring renewed worry.

What this means for you

  • What type of cyst is this likely to be, and how certain is that?
  • Are there worrisome features or high-risk stigmata? Is the main duct widened?
  • Which guideline is my follow-up based on, how often, with which method?
  • Under what circumstances could surveillance end?
  • If surgery is considered: how many such operations does the hospital perform each year?

Ideally, an experienced pancreas team (radiology, gastroenterology, surgery) reviews the first findings once, guarding against both unnecessary operations and missed warning signs. Imaging to look for cysts in people without increased risk makes no sense: the German S3 guideline advises against screening for pancreatic cancer in people without symptoms or increased risk.

Disclosure: the author is a surgeon specialising in liver, pancreatic and bile-duct surgery at LMU Klinikum München and writes here privately.

Bottom line

Most pancreatic cysts are harmless chance findings. Small branch-duct IPMNs without warning signs are watched with MRI according to guidelines; in older people with cysts stable for years, follow-up can end. High-risk stigmata (jaundice, a wall nodule of 5 mm or more, a main duct of 10 mm or more) belong with an experienced pancreas team and lead to surgery in anyone fit for it. Searching for cysts without increased risk brings no benefit.

Evidence: ★★ Moderate for guideline-based surveillance of small branch-duct IPMN (cohort data and consensus); ★★★ High for surgery in high-risk stigmata; — Not recommended: imaging to look for cysts in people without increased risk.

References

  1. Zerboni G, Signoretti M, Crippa S, Falconi M, Arcidiacono PG, Capurso G. Systematic review and meta-analysis: prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology. 2019;19(1):2–9. doi:10.1016/j.pan.2018.11.014 Open article (DOI) ↗
  2. Kromrey ML, Bülow R, Hübner J, Paperlein C, Lerch MM, Ittermann T, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018;67(1):138–145. doi:10.1136/gutjnl-2016-313127 Open article (DOI) ↗
  3. European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67(5):789–804. doi:10.1136/gutjnl-2018-316027 Open article (DOI) ↗
  4. Ohtsuka T, Fernandez-del Castillo C, Furukawa T, Hijioka S, Jang JY, Lennon AM, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas. Pancreatology. 2024;24(2):255–270. doi:10.1016/j.pan.2023.12.009 Open article (DOI) ↗
  5. Vege SS, Ziring B, Jain R, Moayyedi P; AGA Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148(4):819–822. doi:10.1053/j.gastro.2015.01.015 Open article (DOI) ↗
  6. Megibow AJ, Baker ME, Morgan DE, Kamel IR, Sahani DV, Newman E, et al. Management of incidental pancreatic cysts: a white paper of the ACR Incidental Findings Committee. J Am Coll Radiol. 2017;14(7):911–923. doi:10.1016/j.jacr.2017.03.010 Open article (DOI) ↗
  7. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Exokrines Pankreaskarzinom, Version 3.1, September 2024. AWMF-Registernummer 032-010OL.
  8. de la Fuente J, Chatterjee A, Lui J, et al. Long-term outcomes and risk of pancreatic cancer in intraductal papillary mucinous neoplasms. JAMA Netw Open. 2023;6(10):e2337799. doi:10.1001/jamanetworkopen.2023.37799 Open article (DOI) ↗
  9. Marchegiani G, Pollini T, Burelli A, et al. Surveillance for presumed BD-IPMN of the pancreas: stability, size, and age identify targets for discontinuation. Gastroenterology. 2023;165(4):1016–1024.e5. Find on PubMed ↗
  10. Krautz C, Nimptsch U, Weber GF, Mansky T, Grützmann R. Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany. Ann Surg. 2018;267(3):411–417. doi:10.1097/SLA.0000000000002248 Open article (DOI) ↗
Prof. Dr. med. Markus Guba

Head of Liver Surgery and Transplantation at LMU University Hospital Munich. Edits this independent blog in a private capacity; views are his own. About →

This article is general information and not individual medical advice. Decisions about tests and treatment belong in a conversation with your own physician.